02/28
Headlines

MACK

Morning Alert : Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Campus Crest Communities, Inc. (NYSE:CCG), Worthington Industries, Inc. (NYSE:WOR), Facebook Inc (NASDAQ:FB), Google Inc (NASDAQ:GOOG)

Kristen Barton03 mins

Merrimack Pharmaceuticals (NASDAQ:MACK) SVP Edward J. Stewart unloaded 3,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, October 23rd. The shares were sold at an average price of $9.05, for a total transaction of $27,150.00. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) shares moved up 2.07% in last trading session…

Read More

Morning Watch List : Two Harbors Investment Corp. (NYSE:TWO), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Limoneira Company (NASDAQ:LMNR), ATRION Corp. (NASDAQ:ATRI), Ameriprise Financial, Inc. (NYSE:AMP),

Kevin Long03 mins

Two Harbors Investment Corp (NYSE:TWO) declared a quarterly dividend on Tuesday, September 16th, Analyst Ratings.Net reports. Stockholders of record on Tuesday, September 30th will be given a dividend of 0.26 per share on Tuesday, October 21st. This represents a $1.04 dividend on an annualized basis and a yield of 10.25%. The ex-dividend date of this…

Read More

Don’t Miss: Merrimack Pharmaceuticals (NASDAQ:MACK), Acorda Therapeutics (NASDAQ:ACOR), USA Compression Partners, LP (NYSE:USAC), Halliburton Company (NYSE:HAL), Google Inc. (NASDAQ:GOOG)

Kevin Long03 mins

On 4 AUG Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that the company will host its Second Quarter 2014 Investor Conference Call on Monday, August 11. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) belongs to Healthcare sector. Its weekly performance is 12.98%. On last trading day company shares ended up $6.53. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) distance from 50-day simple moving…

Read More

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Ryan Holtz03 mins

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at…

Read More

Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Kristen Barton03 mins

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now…

Read More
Gilead Sciences GILD NASDAQ:GILD

Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton03 mins

InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc…

Read More